MS vs ZYME · P/E 20, $344.27B cap vs rev $76.3M
Morgan Stanley (MS) versus Zymeworks Inc. Common Stock (ZYME) — a side-by-side from cached financials, not a winner call.
Morgan Stanley (MS) is a capital markets company listed on US. It is led by Ted Pick.
Zymeworks Inc. Common Stock (ZYME) is a biotechnology company listed on NASDAQ.
MS does not have a complete income-statement cache yet.
Latest reported ZYME revenue for 2024-12-31 was $76.3M. Net income was -$122.7M. Revenue was up 0.4% from 2023-12-31 to 2024-12-31. ZYME currently screens at market cap $1.68B.
MS currently screens at market cap $344.27B and trailing P/E 19.8. ZYME currently screens at market cap $1.68B.
Not investment advice. Open the MS and ZYME stock pages for the full models.
Not investment advice.